BioMarin Pharmaceutical Inc. (BMRN) Analyst Ratings & Price Targets

BioMarin Pharmaceutical Inc.

BMRN · Nasdaq

Analyst Consensus

Buy

27 analysts

$56

Current

—

Low

$88

Average

—

High

Average target implies +57.71% versus the current price.

Analyst Ratings Synthesis

The supplied sources do not establish a single reconciled consensus, but Public.com reports a Buy rating from 21 analysts and ChartMill cites 34 analysts with an 82.3529 out of 100 consensus score. Published valuation figures are widely dispersed: Simply Wall St.’s fair value is $55.36, Piper Sandler’s target is $84, Public.com cites $90.19, and Jefferies’ target is $105. Jefferies is therefore the most bullish named firm, while Simply Wall St. provides the lowest cited valuation. Jefferies raised its target by $1 to $105 on August 31, before the covered week; no revision during the week is supplied. The substantive disagreement centers on discount rates versus long-term growth and margin improvement.

Rating Actions

2 firms captured

Firm	Analyst	Rating	Price Target	Upside	Date	Source
Jefferies Financial Group Inc.	—	Unrated raised price target	$105from $104	+88.2%	Aug 31, 2026	Open the report this row came from
Piper Sandler	—	Unrated set price target	$84	+50.5%	Feb 6, 2026	Open the report this row came from

Rating actions are extracted from published reporting. Each row links to its source.

Research Reports

Links to freely available third-party research. Outlook labels are our classification of each article's stance, not a rating of our own.

Covering Firms

B OF A GLBL RES

BAIRD R W

BARCLAYS CAPITA

BMO CAPITAL MKT

CANACCORD GENUI

CANTOR FITZGERA

CITIGROUP

CO FORECST

GUGGENHEIM SEC.

JEFFERIES & CO.

JP MORGAN SECUR

LEERINK PARTNRS

MORGAN STANLEY

OPPENHEIMER HLD

PIPER SANDLER

RAYMOND JAMES

RBC CAPITAL

SANFORD BERNSTE

SCOTIABANK

STIFEL NICOLAUS

TD COWEN

TRUIST SECURITI

UBS

WEDBUSH SECURIT

WELLS FARGO SEC

WILLIAM BLAIR

ZACKS RESEARCH

Symbol: BMRN
Type: Stock
Sector: Health Care
Industry: Biotechnology: Pharmaceutical Preparations
Country: North America
Exchange: Nasdaq

BioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients.

Key Issues

Bullish view

The cited targets of $84 from Piper Sandler, $90.19 from Public.com’s analyst summary, and $105 from Jefferies indicate substantial upside-oriented valuation support.

Bearish view

Simply Wall St. places fair value at $55.36, far below the other cited figures, showing that assumptions about discount rates and long-term economics materially change the valuation.

Analyst Consensus

See all

Buy

27 analysts

$56

Current

—

Low

$88

Average

—

High

Average target implies +57.71% versus the current price.

Earnings History

BeatMissNo estimate

BioMarin Pharmaceutical Inc.

Analyst Consensus

Analyst Ratings Synthesis

Rating Actions

Research Reports

Covering Firms

Peers